• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Officer Simpson Andrew acquired 17 shares, increasing direct ownership by 0.22% to 7,629 units (SEC Form 4)

    8/14/24 5:57:51 PM ET
    $HSCS
    Industrial Specialties
    Health Care
    Get the next $HSCS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Simpson Andrew

    (Last) (First) (Middle)
    C/O HEART TEST LABORATORIES, INC.,
    550 RESERVE STREET, SUITE 360

    (Street)
    SOUTHLAKE TX 76092

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Heart Test Laboratories, Inc. [ HSCS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    08/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.001 par value 08/12/2024 J 17 A (1) 7,629(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These shares were transferred to the Reporting Person from the Simpson Family Benefit Trust. The Reporting Person was a beneficiary of such trust, but did not have voting or dispositive power over such shares.
    2. The number of shares takes into account a 1-for-100 reverse stock split of the Company's common stock which became effective on May 17, 2024.
    Remarks:
    Chairman of the Board, President and Chief Executive Officer
    /s/ Andrew Simpson 08/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HSCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSCS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

      Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the signing of its first commercial customer for the MyoVista Insights™ platform: Westcliffe Health Innovations, based in the United Kingdom. This milestone follows the recent launch of MyoVista Insights and the initiation of an early adopter program for reference sites earlier this month. Westcliffe Health Innovations provides cardiology services to the U.K. National Health Service (NHS) in the Bradfor

      5/29/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

      Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson will deliver a live presentation and participate in a Q&A session at the Emerging Growth Conference 82. Event Details: Date: Wednesday, May 21, 2025 Time: 10:15 AM EDT | 7:15 AM PDT Format: Virtual presentation with live Q&A Registration To attend this live, interactive online event, please register though: Emerging Growth Conference 82 This event prov

      5/20/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    SEC Filings

    See more
    • HeartSciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - HeartSciences Inc. (0001468492) (Filer)

      5/28/25 4:51:58 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

      8-K - HeartSciences Inc. (0001468492) (Filer)

      5/19/25 5:29:21 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 253G2 filed by HeartSciences Inc.

      253G2 - HeartSciences Inc. (0001468492) (Filer)

      5/15/25 5:00:04 PM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Financials

    Live finance-specific insights

    See more
    • HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

      Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host conference call on Wednesday, October 25, 2023 Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) --  Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced a conference call to update investors on recent key achievements and positive developments. The conference call will be host

      10/19/23 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bent Bruce

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/23/25 4:30:07 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Officer Hilz Mark T

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 7:21:18 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Wells David R.

      4 - HeartSciences Inc. (0001468492) (Issuer)

      1/21/25 5:17:26 PM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Leadership Updates

    Live Leadership Updates

    See more
    • HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

      Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien

      5/7/25 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Adds Key Advisor to its Scientific Advisory Board

      Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board. "Dr. Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company's technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board," said Andrew Simpson, CEO of HeartSciences. "Dr. Sengupta has

      2/26/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • HeartSciences Expands its Scientific Advisory Board

      Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board. "Dr. Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medi

      2/12/24 9:00:00 AM ET
      $HSCS
      Industrial Specialties
      Health Care

    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      12/11/23 8:30:12 AM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Heart Test Laboratories Inc.

      SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)

      11/27/23 4:02:41 PM ET
      $HSCS
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by Heart Test Laboratories Inc.

      SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)

      6/14/23 5:06:17 PM ET
      $HSCS
      Industrial Specialties
      Health Care